XERS Q3 2020 Earnings — Xeris Biopharma Holdings, Inc. Revenue & Financial Results | Market Cap Arena

XERSXeris Biopharma Holdings, Inc.

$982M

Q3 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$9M+2825.1% YoY

Gross Profit

$7M70.0% margin

Operating Income

-$14M-145.5% margin

Net Income

-$16M-169.3% margin

EPS (Diluted)

$-0.35

QoQ Revenue Growth

+366.1%

Cash Flow

Operating Cash Flow

-$17M

Free Cash Flow

-$17M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$170M

Total Liabilities

$156M

Stockholders' Equity

$14M

Cash & Equivalents

$38M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$9M	$323,000	+2825.1%
Gross Profit	$7M	$313,000	+2013.7%
Operating Income	-$14M	-$30M	+54.3%
Net Income	-$16M	-$33M	+51.3%